1. Medtech Insight
  2. >>Archive

Device Tax Repeal Tops AdvaMed Priority List For Fiscal-Cliff Bill

The post-election, “lame-duck” Congress will face the prospect of letting massive federal spending cuts take effect and multiple tax increases kick in if it does not take action. Device firms hope to leverage the situation to repeal the looming medical device excise tax and make FDA user-fee fixes while avoiding more Medicare provider cuts.

As Congress seeks to avoid going over a “fiscal cliff” later this year, device industry lobbyists see an opportunity to make some policy gains, including a repeal of the impending medical device excise tax. At the same time, companies are anxious to avoid increased reimbursement pressures.

The “lame-duck” Congress that returns to Washington following the Nov. 6 election will face the prospect of letting massive, across-the-board federal spending cuts take effect and multiple tax increases kick...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.